Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years

NCT04026984 is registered in ClinicalTrials.gov with RedHill Biopharma Limited as lead sponsor.

NCT NCT04026984
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04026984 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Double Blind, Multi-center Study to Evaluate the Safety and Efficacy of 100 mg Twice Daily Rifamycin SV MMX® Added to Standard ORT Versus Placebo Plus ORT, in the Treatment of Traveler's Diarrhea in Children Age 6 to 11 Years
Lead sponsor
RedHill Biopharma Limited
Phase
Phase 2
Overall status
Unknown status
Start date
June 30, 2024
Completion date
December 31, 2025
Enrollment
142 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

traveler's diarrhea